Acrivon Therapeutics, Inc Common Stock
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -383 | 911 | -300 | |
EBITDA | -17,564 | -18,659 | -24,833 | -17,885 |
EBIT | -17,964 | -19,042 | -25,194 | -18,234 |
Net Income | -17,964 | -19,042 | -18,985 | -18,234 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -14,949 | -20,552 | -15,456 | -13,182 |
Cash | 41,417 | 34,064 | 41,499 | 35,405 |
Basic Shares | 41,841 | 38,724 | 38,509 | 38,560 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -1,356 | -1,006 | -536 | -1,095 |
EBITDA | -76,549 | -79,550 | -59,852 | -32,293 |
EBIT | -77,905 | -80,556 | -60,388 | -32,657 |
Net Income | -77,905 | -80,556 | -60,388 | -29,677 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -70,084 | |||
Free Cash Flow | -65,334 | -68,437 | -43,929 | -32,283 |
Cash | 41,499 | 39,818 | 36,015 | 29,519 |
Basic Shares | 38,509 | 38,296 | 22,078 | 21,920 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.43 |
2026-03-31 | -$0.49 |
2025-12-31 | -$0.49 |
2025-09-30 | -$0.47 |